<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>SE-0-SE-29-2015-03217-285-12182</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Paper microarrays as comprehensive low-cost point of care diagnostics of paediatric infectious diseases in Uganda (PI-POC)</narrative>
   <narrative xml:lang="SV">Pappersbaserade mikroarrayer som patient-n&#xE4;ra, kostandseffektiv diagnosmetod f&#xF6;r pediatriska infektionssjukdomar i Uganda (PI-POC)</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">BACKGROUND  Infectious diseases are the leading cause of illness in children. When managing bacterial infections it is important and often crucial that antibiotics are given without delay, however the spread of antibiotic resistance due to over-prescription of antibiotics is becoming a major global public health problem and a challenge for clinicians everywhere. Consequently, there is a great need for tools that help clinicians manage febrile children, particularly in resource-limited settings, so that treatments and antibiotic regimens may be guided.  Infections of the central nervous system (CNS) are life-threatening and annually more than 1.2 million cases of bacterial meningitis occur worldwide. Many of these occur in Sub-Saharan African areas with little or no access to laboratory diagnostics and are therefore left undiagnosed and untreated, with fatal outcomes.  There is therefore a great need for diagnostic methods that are applicable to low-income settings.     OBJECTIVES  Development and clinical evaluation of new rapid multiplexed microarray technologies that can be applied as Point-of-Care (POC) diagnostics of paediatric infections of the CNS, with a particular focus on low-income countries.     METHODS  Our partners at Science for Life Laboratory have through extensive research and development shown that paperbased microarray concepts might be applicable as rapid, affordable, durable, easy-to-use, reliable and highly multiplexed diagnostic methods suitable for POC analysis in low-income countries.  Through the use of paperbased protein and DNA microarrays, various biofluids (blood, urine, cerebrospinal fluid, saliva, sputum and others.) can easily be analysed and semiquantitative measurements of different proteins and biomarkers can be presented within minutes.  Levels of blood glucose or inflammatory markers such as CRP, concentrations of electrolytes or the presence of pathogens such as bacteria or viruses in biofluids, are examples of what could be visualised in a time- and resource efficient manner in a low-income setting.  The project is a true translational research project where the Karolinska Institute team will work together with partners at Science for Life Laboratory and the Mbarara University of Science &amp; Technology and M&#xE9;decins Sans Fronti&#xE8;res Epicentre. We will conduct clinical evaluation studies of these novel paperbased microarray concepts of POC. The studies will be conducted at Mbarara Hospital, in South-Western Uganda.    PLANNED STUDIES  A) Development and optimize performance of a) novel combined affinity proteomic assay and b) novel PCR/DNA microarray assay, both amenable for POC diagnostics of paediatric CNS infection in low- and middle-income countries.   B) Evaluation of the new POC techniques by applying them on 273 previously collected samples from paediatric patients in Uganda with suspected CNS infections.   C) Determining the diagnostic accuracy and study the clinical utility and usability of the new POC test on paediatric CNS infections in a prospective study on 300 children with suspected CNS infections in a hospital setting in South-Western Uganda.    SIGNIFICANCE  This project has the potential to significantly improve diagnostics and outcomes of various infectious diseases affecting children in low-income countries. Our highly multidisciplinary and international research team is dedicated to the continued development of the described multiplexed paper-based microarray concepts towards the deployment of a POC tool that tends to the actual needs and requirements of local health personnel in low-income countries.  The success of this research project would be a proof a concept allowing further development of microarray techniques towards POC-testing of other medical conditions, and could assist in spreading the availability of good healthcare to the most vulnerable populations.</narrative>
   <narrative xml:lang="SV">Infektioner &#xE4;r den enskilt st&#xF6;rsta orsaken till sjuklighet och d&#xF6;dlighet hos barn. I h&#xF6;ginkomstl&#xE4;nder g&#xF6;r god tillg&#xE5;ng till sjukv&#xE5;rd att behandlingskr&#xE4;vande infektioner uppt&#xE4;cks och behandlas i ett tidigt skede. I l&#xE5;ginkomstl&#xE4;nder d&#xE4;remot kan brist p&#xE5; n&#xE4;ringsrik mat och rent dricksvatten, l&#xE5;nga avst&#xE5;nd till (eller total avsaknad av) sjukv&#xE5;rdsinr&#xE4;ttningar, otillr&#xE4;ckliga vaccinationsprogram, och allm&#xE4;n resursbrist leda till att lindriga infektioner kan utvecklas till allvarliga.    Sm&#xE5; barn har sv&#xE5;rt att f&#xF6;rmedla sina besv&#xE4;r och ofta &#xE4;r feber enda tecknet till allvarlig sjukdom. F&#xF6;r v&#xE5;rdspersonal kan feber hos ett sp&#xE4;dbarn misst&#xE4;nkas bero p&#xE5; allt ifr&#xE5;n lindrig virusorsakad f&#xF6;rkylning till livshotande bakteriell hj&#xE4;rnhinneinflammation (meningit) och s&#xE4;rskiljandet mellan dessa tv&#xE5; &#xE4;r sv&#xE5;r trots tillg&#xE5;ng till dyr och avancerad laboratorieutrustning. &#xC4;n sv&#xE5;rare &#xE4;r det utan tillg&#xE5;ng till s&#xE5;dan utrustning.    Nya billiga, l&#xE4;ttanv&#xE4;nda och tr&#xE4;ffs&#xE4;kra diagnostiska metoder som st&#xF6;d i avg&#xF6;randet om huruvida feber hos barn st&#xE5;r f&#xF6;r n&#xE5;got livshotande eller ej skulle kunna vara till stor nytta f&#xF6;r v&#xE5;rdspersonal i l&#xE5;ginkomstl&#xE4;nder, med potential att f&#xF6;rb&#xE4;ttra &#xF6;verlevnaden av allvarliga barninfektioner.    V&#xE5;rt forskningsprojekt &#xE4;mnar utv&#xE4;rdera en ny lovande snabbdiagnostisk metod framtagen p&#xE5; Science for Life Laboratory (SciLifeLab), med fokus p&#xE5; dess kliniska till&#xE4;mpbarhet vid misstanke om meningit hos barn, samt dess anv&#xE4;ndbarhet f&#xF6;r v&#xE5;rdspersonal i Mbarara, Uganda.    SciLifeLab har utvecklat ett koncept d&#xE4;r det p&#xE5; sm&#xE5; pappersbitar f&#xF6;rtrycks hundratals millimeterstora prickar. Varje prick utg&#xF6;rs av tusentals antikroppar som endast kan binda upp ett specifikt &#xE4;mne. En prick kan best&#xE5; av antikroppar mot blodsockermolekyler, grannpricken av antikroppar mot infektionsproteiner, osv. F&#xF6;rekomsten av ett &#xE4;mne i den kroppsv&#xE4;tska (blod, snor, slem, urin, ryggm&#xE4;rgsv&#xE4;tska etc.) som analyseras med denna metod resulterar i att det binder till sina specifika antikroppar i pricken, varp&#xE5; pricken &#xE4;ndrar nyans. Olika halter av &#xE4;mnet ger olika nyanser av pricken. De hundratals prickarna kan samtidigt svara p&#xE5; halten av lika m&#xE5;nga &#xE4;mnen i den analyserade v&#xE4;tskan.    Tolkningen av det prickm&#xF6;nster som uppst&#xE5;r p&#xE5; de runda pappersbitarna g&#xF6;rs av en vanlig smartphone d&#xE4;r dess kamera g&#xF6;r en optisk avl&#xE4;sning varp&#xE5; m&#xF6;nstret tolkas av en s&#xE4;rskilt framtagen app. Inom minuter kan man p&#xE5; telefondisplayen avl&#xE4;sa inneh&#xE5;llet i den analyserade kroppsv&#xE4;tskan. Genom att f&#xF6;rbehandla analysmaterialet kan man &#xE4;ven p&#xE5;visa f&#xF6;rekomsten av ev. mikroorganismer, s&#xE5;som bakterier och virus.Analysmetoden kr&#xE4;ver v&#xE4;ldigt lite personaluppl&#xE4;rning och n&#xF6;dv&#xE4;ndig utrustning &#xE4;r billig.    Tekniken bakom denna metod har l&#xE4;nge funnits tillg&#xE4;nglig i graviditetstester, snabbtester f&#xF6;r halsfluss och liknande. D&#xE4;r dessa tester hittills endast svarat p&#xE5; en eller ett f&#xE5;tal fr&#xE5;gest&#xE4;llningar (&#x201D;&#xC4;r jag gravid?&#x201D;) kan metoden fr&#xE5;n SciLifeLab ge svar p&#xE5; m&#xE5;nga fler.    Vi vill studera den praktiska till&#xE4;mpningen och nyttan av denna metod i en klinisk omgivning d&#xE4;r konventionell laboratorieutrustning &#xE4;r en bristvara.    Tack vare ett samarbete med Mbarara Hospital och L&#xE4;kare Utan Gr&#xE4;nsers forskningslaboratorium i Mbarara, Uganda, har vi p&#xE5; ett tidigt stadium kunnat inh&#xE4;mta &#xF6;nskem&#xE5;l om egenskaper en idealisk POC-metod b&#xF6;r ha i f&#xE4;lt. Utifr&#xE5;n dessa har vi i samr&#xE5;d beslutat att fokusera den f&#xF6;rsta kliniska utv&#xE4;rderingen av metodens anv&#xE4;ndbarhet p&#xE5; diagnostik av meningit. Bakteriell meningit drabbar &#xE5;rligen ca 1,2 miljoner barn och utan snabb behandling uppg&#xE5;r d&#xF6;dligheten till n&#xE4;rmre 100 %.  Symtom p&#xE5; meningit kan till en b&#xF6;rjan vara diskreta och f&#xF6;r att bekr&#xE4;fta en misstanke om meningit kr&#xE4;vs insamling, analys och bakterieodling av den sjukes ryggm&#xE4;rgsv&#xE4;tska.  Detta st&#xE4;ller idag krav p&#xE5; utbildad personal samt en viss infrastruktur f&#xF6;r analys och odling av v&#xE4;tskan, n&#xE5;got som inte kan tillgodoses i l&#xE5;ginkomstomr&#xE5;den som Mbarara. Detta leder ofta till felaktig diagnostik och behandling, och bidrar till en fortsatt farl</narrative>
  </description>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-29" role="3" type="10">
   <narrative xml:lang="EN">The Swedish Research Council</narrative>
  </participating-org>
  <participating-org ref="51000" role="4" type="80">
   <narrative xml:lang="EN">University, college or other teaching institution, research institute or think-tank</narrative>
  </participating-org>
  <activity-status code="3"></activity-status>
  <activity-date iso-date="2016-01-01" type="1"></activity-date>
  <activity-date iso-date="2019-12-31" type="3"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">The Swedish Research Council</narrative>
   </organisation>
   <telephone>+46 8 546 44 000</telephone>
   <email>vetenskapsradet@vr.se</email>
   <website>www.vr.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Box 1035, 101 38 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="UG" percentage="100">
   <narrative xml:lang="EN">Uganda</narrative>
  </recipient-country>
  <sector code="121" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Health, General</narrative>
  </sector>
  <sector code="12182" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Medical research</narrative>
  </sector>
  <tag code="3.B" vocabulary="3">
   <narrative xml:lang="SV">3.b - St&#xF6;dja forskning om och utveckling av vaccin och l&#xE4;kemedel mot de smittsamma och icke-smittsamma sjukdomar som i f&#xF6;rsta hand drabbar utvecklingsl&#xE4;nder. S&#xF6;rja f&#xF6;r tillg&#xE5;ng till ekonomiskt &#xF6;verkomliga grundl&#xE4;ggande l&#xE4;kemedel och vaccin, i enlighet med Doha-deklarationen om TRIPS-avtalet och folkh&#xE4;lsa, i vilken det bekr&#xE4;ftas att utvecklingsl&#xE4;nderna har r&#xE4;tt att fullt ut utnyttja den flexibilitet som avtalet om handelsrelaterade aspekter av immaterialr&#xE4;tter erbjuder f&#xF6;r att skydda folkh&#xE4;lsan och, framf&#xF6;r</narrative>
   <narrative xml:lang="EN">3.b - Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public healt</narrative>
  </tag>
  <policy-marker code="5" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="11" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disability</narrative>
  </policy-marker>
  <policy-marker code="10" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disaster Risk Reduction(DRR)</narrative>
  </policy-marker>
  <policy-marker code="1" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="1" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="D02" vocabulary="1"></default-aid-type>
  <default-tied-status code="4"></default-tied-status>
  <budget>
   <period-start iso-date="2016-01-01"></period-start>
   <period-end iso-date="2016-12-28"></period-end>
   <value currency="USD" value-date="2016-01-01">126804.1839537194</value>
  </budget>
  <budget>
   <period-start iso-date="2017-01-01"></period-start>
   <period-end iso-date="2017-12-28"></period-end>
   <value currency="USD" value-date="2017-01-01">126945.1269451269</value>
  </budget>
  <budget>
   <period-start iso-date="2018-01-01"></period-start>
   <period-end iso-date="2018-12-28"></period-end>
   <value currency="USD" value-date="2018-01-01">124850.409647427</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2015-11-27"></transaction-date>
   <value currency="USD" value-date="2015-11-27">386153.0613455447</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-01-28"></transaction-date>
   <value currency="USD" value-date="2016-01-28">126804.1839537194</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-01-28"></transaction-date>
   <value currency="USD" value-date="2017-01-28">126945.1269451269</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-01-28"></transaction-date>
   <value currency="USD" value-date="2018-01-28">124850.409647427</value>
  </transaction>
  <crs-add>
   <other-flags code="1" significance="1"></other-flags>
  </crs-add>
  <sida:contribution xmlns:sida="http://sida.se/ns/contribution#"></sida:contribution>
 </iati-activity>
</iati-activities>
